New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
10:57 EDTCREE, OPK, KING, PSEC, YPF, ICPT, ACRX, TAX, CALL, ARWROptions with decreasing implied volatility
Options with decreasing implied volatility: ARWR ICPT KING CALL YPF OPK TAX PSEC CREE ACRX
News For ARWR;ICPT;KING;CALL;YPF;OPK;TAX;PSEC;CREE;ACRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
16:13 EDTICPTIntercept submits applications for marketing approval of Obeticholic Acid
Subscribe for More Information
June 26, 2015
12:58 EDTOPKOn The Fly: Top stock stories at midday
Stocks on Wall Street were mixed at midday, with Nike's (NKE) post-earnings rise providing a boost to the Dow and Micron's (MU) slide dragging on the tech-heavy Nasdaq. ECONOMIC EVENTS: In the U.S., the University of Michigan consumer sentiment reading rebounded to 96.1 in the final June report from the preliminary 94.6 reading. That revised figure topped the expected reading of 95. In Europe, the ECB left the level of emergency cash available to Greek banks unchanged again Friday as deposit outflows have slowed, according to people familiar with the matter reporting to Bloomberg. Greek leaders are scheduled to hold talks Saturday with the Eurogroup in what may be the nation's last chance for a deal ahead of the expiration of the current bailout agreement on June 30. In China, stocks plunged by the most in five months as the Shanghai Composite Index fell 7.4%, with market watchers citing margin worries and concerns that the PBOC will be less likely to undertake further rate cuts. COMPANY NEWS: Shares of Nike advanced 4% after the athletic apparel and sneaker maker reported fourth quarter results that handily beat expectations. Several firms raised their respective price targets on the stock following the company's Q4 report, including Goldman, which reiterated its Conviction Buy rating on Nike and raised its price target to $131 from $121. Finish Line (FINL), an athletic shoe and apparel retailer that sells Nike products, rose 5% after its own first quarter results also topped the consensus forecast. MAJOR MOVERS: Among the notable gainers was OPKO Health (OPK), which rose nearly 4% after the company announced the decision of the National Comprehensive Cancer Network to include 4Kscore as a recommended test in the 2015 NCCN Guidelines for Prostate Cancer Early Detection. Additionally, CEO Phillip Frost disclosed in regulatory filings that he'd acquired over 64,000 shares of the company stock in the last two days. Also higher was Kforce (KFRC), which gained 7% after SunTrust upgraded the stock to Buy and raised its price target to $27 from $24, noting that the firm's private IT staffing poll suggests margin assumptions may prove conservative. Among the noteworthy losers was Micron, which sunk about 19% after the flash memory maker reported weaker than expected results last night and provided lower than expected Q4 revenue guidance. Also lower were shares of coal miner Peabody (BTU), which fell 7% after Moody's downgraded the company's credit rating to reflect the firm's expectation for the deterioration in the company's credit metrics to be more precipitous than it had previously thought due to the ongoing decline in the seaborne metallurgical coal markets. INDEXES: Near midday, the Dow was up 53.70, or 0.3%, to 17,944.06, the Nasdaq was down 40.56, or 0.79%, to 5,071.62, and the S&P 500 was down 2.18, or 0.1%, to 2,100.13.
11:46 EDTOPKOpko Health shares advance after CEO buys shares
Shares of OPKO Health are advancing after the company CEO Phillip Frost disclosed in a filing this morning that he'd acquired 7,200 shares of the company stock for $15.39 per share on June 25. The CEO's share purchases follow a disclosure yesterday morning that he'd purchased 57,200 shares of the company stock for $15.33 per share on June 24. Opko Health shares are up 3.6% to $15.97 in late morning trading.
10:26 EDTOPKOPKO 4Kscore recommended in NCCN guidelines for prostate cancer early detection
OPKO Health announced the decision of the National Comprehensive Cancer Network to include 4Kscore as a recommended test in the 2015 NCCN Guidelines for Prostate Cancer Early Detection. The panel concluded that the 4Kscore, as a blood test with greater specificity over the PSA test, is indicated for use prior to a first prostate biopsy or after a negative biopsy to assist patients and physicians in further defining the probability of high-grade cancer. The 4Kscore test has been studied on over 22,000 patients with results published in 12 peer-reviewed scientific publications.
05:51 EDTCREECree to downsize LED capacity due to price competition from China, DigiTimes say
Subscribe for More Information
June 25, 2015
12:51 EDTCREEOn The Fly: Top stock stories at midday
Stocks on Wall Street opened higher but quickly gave up most of their gains as investors awaited news of a deal being reached between Greece and its creditors. The averages bounced back when the Supreme Court issued its ruling upholding ACA subsidies, sending a number of healthcare linked stocks higher. The market remained in positive ground near noon, but well off its best levels. ECONOMIC EVENTS: In the U.S., personal income rose 0.5% in May, matching the consensus expectation, while spending rose 0.9%, topping the expected 0.7% increase. Initial jobless claims were 271,000 in the week ended June 20, versus expectations for 273,000 first-time claims. Markit's services index fell to 54.8 for the flash June reading, versus expectations for a rise to 56.5 from the 56.2 May reading. The Kansas City Fed manufacturing survey for June came in at -9, as expected. COMPANY NEWS: Shares of hospital operators and health insurers rose after the Supreme Court upheld the legality of subsidies provided under the framework of the Affordable Care Act. The 6 to 3 decision in the Burwell versus King case means that the government can continue to offer subsidies to low income people who purchase health insurance plans on the federal exchange. The plaintiffs in the case had asked the court to strike down such subsidies, saying that the ACA had only allowed the government to subsidize insurance bought on exchanges created by states. In the wake of the ruling, which has been eagerly anticipated, Tenet Healthcare (THC) and Community Health (CYH) both rose more than 14%, while HCA Holdings (HCA) advanced nearly 9%. MAJOR MOVERS: Among the notable gainers was IAC/InterActiveCorp (IACI), which advanced 5% after announcing that its board has approved the pursuit of an initial public offering for The Match Group, which includes dating website Match.com and mobile dating app Tinder. IAC expects Match Group to issue less than 20% of its common stock in the IPO, which is seen being completed during the fourth quarter of this year. Also higher was Magnum Hunter (MHR), which gained 5% after disclosing that it has now determined to pursue the sale by the company of 100% of its current equity ownership interest in Eureka Hunter Holdings. Among the noteworthy losers was World Acceptance (WRLD), which dropped 19% after the company entered into an amendment with its lenders on its revolving credit agreement. FBR Capital downgraded the stock to Market Perform and cut its price target for shares to $73 from $98 afterward, saying restrictive covenants in the latest amendment means free cash flow will now be used to pay down debt rather than buy back stock. Also lower were shares of Cree (CREE), which fell about 11% after the company announced last night that it has decided to restructure its LED Products business to reduce excess capacity and overhead following recent market trends that have resulted in higher LED average selling price erosion than previously forecast. Cree also lowered its Q4 revenue view and issued FY16 revenue guidance that was below the consensus expectation. INDEXES: Near midday, the Dow was up 18.88, or 0.11%, to 17,984.95, the Nasdaq was up 5.87, or 0.11%, to 5,128.29, and the S&P 500 was up 2.18, or 0.1%, to 2,110.76.
10:46 EDTCREECree tumbles on LED business restructuring, bearish pattern
Subscribe for More Information
07:24 EDTCREECree price target lowered to $35 from $39 at JPMorgan
Subscribe for More Information
June 24, 2015
19:01 EDTCREEOn The Fly: After Hours Movers
UP AFTER EARNINGS: Herman Miller (MLHR), up 5.1%. ALSO HIGHER: Turtle Beach (HEAR), up 3.6% after partnering with AuDConnex for direct audio hearing solution. DOWN AFTER EARNINGS: Bed Bath & Beyond (BBBY), down 2.6%. ALSO LOWER: Cree (CREE), down 5.1% after lowering fourth quarter revenue outlook... Sabra Health Care (SBRA), down 2.7% after filing to sell 5M shares of common stock at a price range of $25.25-$25.65.
16:55 EDTCREECree down over 5% after lowering Q4 revenue outlook
Subscribe for More Information
16:08 EDTCREECree targets FY16 revenue of $1.8B, consensus $1.89B
Targets FY16 operating margin to increase approximately 8%; FY16 free cash flow of approximately $75M.
16:06 EDTCREECree lowers Q4 revenue view to approximately $375M from $420M-$440M
Q4 consensus $430.82M. Guidance includes $27M revenue reserve. Lighting Products revenue is targeted to increase slightly sequentially, as strong growth in commercial lighting is expected to more than offset a greater-than-targeted seasonal slowdown in consumer bulb sales. Power & RF Products revenue is tracking in-line with the company’s targets for fiscal Q4. LED Products customer unit demand is generally in-line with our targets for the quarter; however, the combination of the revenue reserves and lower pricing in the quarter is forecast to reduce fiscal Q4 revenue by approximately $35M. Overall gross margin and operating margin are now forecast to be lower than previously targeted due to the restructuring costs, the more aggressive LED pricing environment, and the larger than targeted seasonal slowdown in consumer lighting. During fiscal Q4, the company completed the previously announced $550M share buyback program by repurchasing 4.8M shares of its common stock at an average price of $33.37 per share, with an aggregate value of $160M. For fiscal year 2015, the company repurchased 16M shares of its common stock at an average price of $34.33.
16:04 EDTCREECree announces restructuring of LED products business
Subscribe for More Information
16:02 EDTCREECree announces $500M stock buyback authorization for FY16
Subscribe for More Information
June 21, 2015
14:16 EDTOPKOPKO Health shares look pricey, Barron's says
Investors should steer clear of OPKO Health (OPK) and Bio-Reference Labs (BRLI) in light of their recent merger agreement, Barron's contends in a feature article. Though OPKO hopes to push its prostate cancer test, similar products have performed poorly on the market, and Barron's advises "only those who believe that [CEO and chairman Phillip Frost] can work miracles" to own the stock. Reference Link
June 19, 2015
13:27 EDTTAXLiberty Tax advances after reporting Q4 results
Subscribe for More Information
08:35 EDTTAXWheeler REIT appoints Matthew Reddy as Chief Accounting Officer
Wheeler Real Estate Investment Trust (WHLR) announced that the company has appointed Matthew Reddy as Chief Accounting Officer. In this newly created position, Reddy will oversee all aspects of the company’s accounting department and will assist Wheeler’s chief financial officer in all aspects of accounting and regulatory compliance. Prior to joining the company, Reddy was the Assistant Vice President of Online Products at Liberty Tax Service (TAX).
June 17, 2015
07:36 EDTARWRArrowhead receives regulatory clearance for additional Phase 2b ARC-520 studies
Arrowhead Research announced that its Clinical Trial Application for ARC-520, its clinical candidate for chronic hepatitis B infection, has been approved by Germany’s Federal Institute for Drugs and Medical Devices. The company now has regulatory clearance in Germany for two additional Phase 2b multiple-dose studies of ARC-520 to be conducted in parallel. Arrowhead awaits final IRB approval from the sites, which are expected shortly, and in addition, the company is engaged with regulatory authorities from Hong Kong and South Korea to open additional sites for these studies. Arrowhead will provide guidance in the future on timing for release of data from these studies. The studies titled Heparc-2002 and Heparc-2003 will enroll patients with chronic HBV infection that are e-antigen negative and HBeAg positive, respectively. Each study is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study intended to evaluate two dose levels in parallel of ARC-520 in combination with entecavir or tenofovir in patients with immune active chronic HBV infection. The 2002 and 2003 studies are planned to enroll up to 60 and 90 patients, respectively. In each study, patients will be randomized to receive four doses, once every 4 weeks, of either 1 mg/kg ARC-520, 2 mg/kg ARC-520, or placebo at a ratio of 1:1:1. For each patient, the duration of the study is approximately 33 weeks, from screening to the Day 169 follow-up visit. For each study, a planning interim analysis will be performed when 54 patients have completed their Day 71 visit. This analysis will be used to plan future studies only and will not impact the enrollment or conduct of Heparc-2002 and -2003. Based on the interim results, the company will decide whether higher multiple-doses would be likely to lead to increased activity, in which case higher doses may be evaluated in one or more additional studies. The primary objective of the 2002 and 2003 studies is to evaluate the depth of hepatitis B surface antigen decline in response to multiple doses of ARC-520 compared to placebo as a measure of drug activity. Secondary objectives include the assessment of safety and tolerability and multi-dose pharmacokinetics of ARC-520 when co-administered with entecavir or tenofovir, in addition to other exploratory objectives.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use